Consensus for the treatment of adolescent patients with PCOS
I apologize for the different format but I am trying something new from my handheld, because I was in the office and wanted to strike while the iron is hot.
So While I have been promoting education and learning about disease mechanism and treatment options, it has drawn some attention in my patient population. Happy to say, I have been successful in getting the word out, but unhappy to see an increase in adolescent PCOS. While this may be a result of ‘The pink Elephant effect’ I am seeing a younger population. This is indeed welcome because this is precisely the time for better and more meaningful lifestyle modifications based on scientific rigor.
Here present the most up-to-date consensus for treatment options in adolescent patients with polycystic ovary syndrome (PCOS) emphasizes a stepwise, individualized approach. The Endocrine Society, as part of the 2023 International Evidence-Based Guideline, recommends that first-line therapy is lifestyle intervention—including dietary modification, increased physical activity, and weight management—due to its benefits for metabolic, reproductive, and psychological outcomes.[1][2][3][4] No specific diet is superior, but calorie reduction and healthy eating patterns are encouraged.
Combined oral contraceptive pills (COCs) are the preferred first-line pharmacologic treatment for menstrual irregularity and clinical hyperandrogenism, with a preference for low-dose ethinyl estradiol preparations to minimize side effects.[1][2][3][5] COCs are also effective for acne and hirsutism.
Metformin is considered for adolescents with metabolic features (e.g., insulin resistance, impaired glucose tolerance, or obesity) and may also help with menstrual regulation, especially if COCs are contraindicated or not tolerated.[1][2][6][3][7][8] Typical dosages in studies range from 1500–2550 mg/day.[7] Metformin is associated with modest reductions in BMI and improvements in insulin sensitivity and lipid profiles.[6][8]
Emerging non-hormonal options, such as SPIOMET (spironolactone, pioglitazone, and metformin) and flutamide plus metformin, show promise for multi-domain efficacy (metabolic, reproductive, and androgenic features), but require further study before routine use.[6] There is insufficient adolescent-specific evidence for GLP-1 receptor agonists.[6][7]
Nutritional strategies, including low-calorie ketogenic diets, may offer short-term metabolic benefits, but long-term safety and sustainability in adolescents remain unclear.[9][10]
Psychological assessment and support are essential due to the high prevalence of anxiety, depression, and eating disorders in this population.[1][2]
In summary, lifestyle modification is first-line, COCs are first-line pharmacologic therapy for menstrual and androgenic symptoms, and metformin is indicated for metabolic dysfunction or COC intolerance. All management should be individualized and incorporate shared decision-making.[1][2][3]
References
1. International Evidence-Based Recommendations for Polycystic Ovary Syndrome in Adolescents. Peña AS, Witchel SF, Boivin J, et al. BMC Medicine. 2025;23(1):151. doi:10.1186/s12916-025-03901-w.
2. Recommendations From the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Teede HJ, Tay CT, Laven JJE, et al. The Journal of Clinical Endocrinology and Metabolism. 2023;108(10):2447-2469. doi:10.1210/clinem/dgad463.
3. Practical Considerations for Diagnosis and Treatment of Polycystic Ovary Syndrome in Adolescence - Distilling Guidelines Into Clinical Practice. DiVall SA. Current Opinion in Pediatrics. 2023;35(4):494-499. doi:10.1097/MOP.0000000000001255.
4. Effect of Lifestyle Modifications on Polycystic Ovary Syndrome in Predominantly Young Adults: A Systematic Review. Long JR, Parker M, Jumani S, et al. Journal of Pediatric and Adolescent Gynecology. 2025;38(2):139-147.e4. doi:10.1016/j.jpag.2024.11.003.
5. Polycystic Ovary Syndrome in Adolescence. Joham AE, Peña AS. Seminars in Reproductive Medicine. 2022;40(1-02):e1-e8. doi:10.1055/s-0042-1757138.
6. Non-Hormonal Pharmacological Interventions in Adolescent Polycystic Ovary Syndrome (PCOS): A Systematic Review. Sibal R, Keogh M, Latthe P, Idkowiak J. Journal of Pediatric and Adolescent Gynecology. 2026;:S1083-3188(26)00001-X. doi:10.1016/j.jpag.2026.01.001.
7. Non-Hormonal Treatment Options for Regulation of Menstrual Cycle in Adolescents With PCOS. Reiser E, Lanbach J, Böttcher B, Toth B. Journal of Clinical Medicine. 2022;12(1):67. doi:10.3390/jcm12010067.
8. Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-Analysis. Al Khalifah RA, Florez ID, Dennis B, Thabane L, Bassilious E. Pediatrics. 2016;137(5):e20154089. doi:10.1542/peds.2015-4089.
9. Low-Calorie Ketogenic Diet: Potential Application in the Treatment of Polycystic Ovary Syndrome in Adolescents. Calcaterra V, Cena H, Sottotetti F, et al. Nutrients. 2023;15(16):3582. doi:10.3390/nu15163582.
10. High Fat Diet and Polycystic Ovary Syndrome (PCOS) in Adolescence: An Overview of Nutritional Strategies. Calcaterra V, Magenes VC, Massini G, et al. Nutrients. 2024;16(7):938. doi:10.3390/nu16070938.